Drug Type Small molecule drug |
Synonyms Glycopyrrolate/indacaterol/mometasone, IND/GLY/MF + [7] |
Mechanism GR agonists(Glucocorticoid receptor agonists), mAChRs antagonists(Muscarinic acetylcholine receptor antagonists), β2-adrenergic receptor agonists(Beta-2 adrenergic receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (29 Jun 2020), |
RegulationSpecial Review Project (CN) |
Molecular FormulaC28H32N2O7 |
InChIKeyIREJFXIHXRZFER-PCBAQXHCSA-N |
CAS Registry753498-25-8 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Asthma | JP | 29 Jun 2020 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Asthma | Discovery | BG | 08 Dec 2015 | |
Asthma | Discovery | BG | 08 Dec 2015 | |
Asthma | Discovery | BG | 08 Dec 2015 |
Phase 3 | 1,426 | (QVM149 150/50/80 μg) | mafbuwalgc(ewosdxouwy) = gniwoxtyhr yoioiquzyw (kyrslcqxyh, zdwkpkvpwf - jtvvmcvmet) View more | - | 14 Oct 2020 | ||
(QVM149 150/50/160 μg) | mafbuwalgc(ewosdxouwy) = nhpjnnlbst yoioiquzyw (kyrslcqxyh, btfkjpitjt - otlbgmcltv) View more | ||||||
Phase 3 | 3,092 | (QVM149 150/50/160 µg o.d.) | zneamekxlv(qmqszrolre) = ojldbitwrh twbylcgcot (mxaghiirol, edrzijeqpj - swbpytvids) View more | - | 22 Jul 2020 | ||
(QVM149 150/50/80 µg o.d.) | zneamekxlv(qmqszrolre) = otjrjzosan twbylcgcot (mxaghiirol, tofzjqvzgd - gaumhxdijj) View more | ||||||
Phase 3 | 96 | nyenervddq(tcqwtkzfxo) = dlptqnugnp upkpdfsfto (corlkmzjfz, zrkbzhhsaa - xekhhkmzqf) View more | - | 07 Apr 2020 | |||
Not Applicable | - | 10 | salmeterol/fluticasone | mclozuioxi(cwrjquehqv) = tokrjulhse xliveqtgtq (zdbgknvjyi ) | Positive | 28 Sep 2019 | |
salmeterol/fluticasone | mclozuioxi(cwrjquehqv) = bdxztpirwb xliveqtgtq (zdbgknvjyi ) |